A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 266 participants.

Also called NCT05188417

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 266 participants (enrolled count) (from the registry)
Sponsor
GrandPharma (China) Co., Ltd. (from the registry)
Registry
  • NCT NCT05188417
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05188417. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-09 (actual); primary completion 2023-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
Acronym
RESET
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tirofiban 0.05 MG/ML
Intervention (Drug)
0.9% sodium chloride solution
Lead sponsor
GrandPharma (China) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05188417
Content hash
924a11b08c7af95750d0810b88d7bf36defddf72492447dfb0814d2350e5597a